Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9GZS0
UPID:
DNAI2_HUMAN
Alternative names:
Axonemal dynein intermediate chain 2
Alternative UPACC:
Q9GZS0; C9J0S6; Q8IUW4; Q9H179; Q9NT53
Background:
Dynein axonemal intermediate chain 2, also known as Axonemal dynein intermediate chain 2, plays a crucial role in the dynein complex of respiratory cilia. This protein is pivotal for the proper function and structural integrity of motile cilia, which are essential for respiratory health and fertility.
Therapeutic significance:
Mutations in Dynein axonemal intermediate chain 2 are directly linked to Primary ciliary dyskinesia, a disorder marked by chronic respiratory infections and reduced fertility. Understanding the role of Dynein axonemal intermediate chain 2 could open doors to potential therapeutic strategies for this condition.